Inmune Bio, Inc. Aktie News

Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC.  The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City.

INmune Bio, Inc. (NASDAQ:INMB ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Christopher Barnum - Corporate Participant Daniel Carlson - Corporate Participant David J. Moss - CFO, Treasurer & Secretary Mark William Lowdell - Chief Scientific Officer & Chief Manufacturing Officer Raymond Joseph Tesi - Co-Founder, President, CEO, Chief Medical Officer & Chairman...

INmune Bio (INMB) Q2 Loss Widens 110%

BOCA RATON, FL, Aug. 04, 2025 (GLOBE NEWSWIRE) --  INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with metastatic castration-resistant prostate cancer (mCRPC) has met its primary and secondary endpoints and is now closed to further enrollment.

Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”),  a clinical-stage inflammation and immunology company, today announced that it will host a conference call on Thursday, August 7th, 2025 at 4:30pm EDT to discuss results for its quarter ended June 30, 2025 and to provide ...

Boca Raton, July 29, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, a novel selective soluble TNF inhibitor, will be published on the company's YouTube Channel following the conclusion of Alzheimer's Association International Conference (AAIC) in Toronto, Canada.

INmune Bio's XPro missed its Phase II primary endpoint, but subgroup data and safety profile suggest potential for targeted Alzheimer's patients with neuroinflammation. Despite the setback, I see significant upside from XPro and CORDStrom, with blockbuster potential if approved, given INMB's tiny current market cap. Risks include uncertain XPro efficacy, need for more capital, and dilution; I m...

Boca Raton, Florida, June 30, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company, today announced that it has closed its registered direct offering, announced on June 27, 2025, (the "Offering") for the purchase and sale of 3,000,000 shares of its common stock at a purchase price of $6.30 per share, priced at-the-market u...